ELDECORT Drug Patent Profile

Which patents cover Eldecort, and when can generic versions of Eldecort launch?

Eldecort is a drug marketed by Valeant Pharm Intl and is included in two NDAs.

The generic ingredient in ELDECORT is hydrocortisone. There are sixty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eldecort

A generic version of ELDECORT was approved as hydrocortisone by IMPAX LABS INC on March 30^th, 2007.

Summary for ELDECORT

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	8
Patent Applications:	4,522
DailyMed Link:	ELDECORT at DailyMed

Recent Clinical Trials for ELDECORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 1
Children's Oncology Group	Phase 1
EsPhALL network I-BFM Study Group	Phase 3

See all ELDECORT clinical trials

US Patents and Regulatory Information for ELDECORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharm Intl	ELDECORT	hydrocortisone	CREAM;TOPICAL	080459-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharm Intl	ELDECORT	hydrocortisone	CREAM;TOPICAL	084055-001	Approved Prior to Jan 1, 1982		DISCN	No	No

EU/EMA Drug Approvals for ELDECORT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch	Plenadren	hydrocortisone	EMEA/H/C/002185 Treatment of adrenal insufficiency in adults.	Authorised	no	no	no	2011-11-03
Diurnal Europe B.V.	Alkindi	hydrocortisone	EMEA/H/C/004416 Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old).	Authorised	no	no	no	2018-02-09
Diurnal Europe B.V.	Efmody	hydrocortisone	EMEA/H/C/005105 Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.	Authorised	no	no	no	2021-05-27

ELDECORT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Oncology Drugs: A Focus on the Broader Context

While the specific drug "ELDECORT" is not mentioned in the provided sources, we can analyze the market dynamics and financial trajectory of the broader oncology drugs market, which can provide insights into the potential trends and factors influencing drugs within this category.

Global Oncology Drugs Market Overview

The global oncology drugs market is experiencing rapid growth, driven by several key factors. As of 2024, the market is valued at $231.56 billion and is projected to reach $532.91 billion by 2031, growing at a compound annual growth rate (CAGR) of 12.6% during the forecast period[1].

Market Drivers

Rising Cancer Prevalence

The increasing prevalence of various cancers globally is a significant driver of the oncology drugs market. This rise in cancer cases necessitates the development and adoption of innovative treatment options.

Adoption of Targeted Therapies and Immunotherapies

The adoption of targeted therapies and immunotherapies is another key driver. These treatments have shown higher efficacy and reduced side effects compared to traditional chemotherapy, leading to increased demand[1].

Market Segmentation

By Drug Class

• Cytotoxic Drugs: Currently, cytotoxic drugs hold a dominant position, expected to account for over 35% of the market share in 2024. However, targeted therapies are anticipated to surpass cytotoxic drugs by 2031 due to their growing clinical evidence and potential[1].

By Therapy

• Chemotherapy: Chemotherapy currently holds the largest share due to its established role in treating both solid and liquid tumors. However, targeted therapy and immunotherapy segments are expected to exhibit significant growth rates due to the development of novel mechanisms and drugs[1].

Regional Analysis

The oncology drugs market is segmented geographically into North America, Europe, Asia Pacific, and the Rest of the World. North America currently holds a significant market share, while the Asia Pacific region is predicted to be the fastest-growing during the forecast period[1].

Financial Trajectory

Revenue Forecast

The market is expected to grow from $231.56 billion in 2024 to $532.91 billion by 2031. This growth is driven by the increasing demand for innovative treatments and the expansion of targeted therapies[1].

Research and Development Expenses

Companies in the oncology sector are investing heavily in research and development. For example, Elicio Therapeutics reported research and development expenses of $8.18 million in the second quarter of 2024, up from $4.94 million in the same period in 2023[2].

Challenges and Restraints

High Development Costs

The development of oncology drugs is highly costly, which can be a significant restraint for market growth. High research and development expenses, along with the need for extensive clinical trials, contribute to these costs[1].

Stringent Government Regulations

Stringent government regulations and the rigorous approval process for new drugs also pose challenges to the market. Companies must navigate complex regulatory frameworks to bring new treatments to market[1].

Innovations and Trends

Targeted Drug Delivery Systems

Advancements in targeted drug delivery systems have led to the development of innovative drugs with higher efficacy and reduced side effects. These innovations are driving market growth and improving patient outcomes[1].

Precision Medicine and Personalized Treatment

The trend towards precision medicine and personalized treatment is also shaping the market. Extended-release drugs, for example, are seeing rapid growth due to their improved efficacy and patient compliance[4].

Key Takeaways

• The global oncology drugs market is expected to grow significantly, driven by rising cancer prevalence and the adoption of targeted therapies.
• Cytotoxic drugs currently dominate the market but are expected to be surpassed by targeted therapies by 2031.
• High development costs and stringent government regulations are key restraints.
• Innovations in drug delivery systems and precision medicine are driving market growth.

FAQs

What is the projected growth rate of the global oncology drugs market?

The global oncology drugs market is anticipated to grow at a CAGR of 12.6% from 2024 to 2031[1].

Which segment is expected to dominate the oncology drugs market by 2031?

The targeted therapy segment is expected to emerge as the largest segment by 2031, surpassing cytotoxic drugs[1].

What are the main drivers of the oncology drugs market?

The main drivers include the rising prevalence of cancer globally and the increasing adoption of targeted therapies and immunotherapies[1].

What are the significant challenges facing the oncology drugs market?

High development costs and stringent government regulations are significant challenges[1].

How are innovations in drug delivery systems impacting the market?

Innovations in targeted drug delivery systems are leading to the development of drugs with higher efficacy and reduced side effects, driving market growth[1].

Cited Sources:

1. Coherent Market Insights, "Oncology Drugs Market to Reach USD 532.91 Billion by 2031".
2. Elicio Therapeutics, "Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates".
3. GlobeNewswire, "Controlled Substance Market Report 2024: Forecasts Reveal Strong Growth in Asia-Pacific Region".
4. The Business Research Company, "Global Extended Release Drugs Market Report 2024".